Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00767689 · ClinicalTrials.gov registry record · NA
Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy
A NA study, sponsored by Cook County Health.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT00767689: Clinical Trial NA study, sponsored by Cook County Health.
NCT00767689 is a NA study that was terminated before completion, run by Cook County Health. The registered enrollment target is 6 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00767689, a NA study, was terminated before completion, sponsored by Cook County Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
Capecitabine (Xeloda) a drug in cancer therapy. Its use is limited often by its toxicities. This study is asking if vitamin B6 can prevent one of the common toxicities of xeloda which is numbness and/or rash of the hands and feet, a condition called Hand and Foot syndrome. patients , starting capecitabine chemotherapy for their cancer, will participate in this study at John H. Stroger Jr. Hospital of Cook County. They will be randomized to receive either vitamin B6 or a placebo. investigators and patients will be blinded to the intervention.
Primary Outcome
Incidence of HFS based on CTCTAE adverse event table
Interventions
- DRUG placebo
- DRUG Vitamin B 6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2006-03-21 |
| Est. Completion | 2010-03-17 |
| Phase | NA |
Why NCT00767689 stopped before completion
NCT00767689 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00767689 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00767689 about?
NCT00767689 is a clinical study titled "Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Capecitabine Chemotherapy". Capecitabine (Xeloda) a drug in cancer therapy. Its use is limited often by its toxicities. This study is asking if vitamin B6 can prevent one of the common toxicities of xeloda which is numbness and/or rash of the hands and feet, a condition called Hand and Foot syndrome. patients , starting capeci...
What is the current status of trial NCT00767689?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2006-03-21. Estimated completion is 2010-03-17.
What interventions are being tested in trial NCT00767689?
The interventions under investigation include: placebo (DRUG), Vitamin B 6 (DRUG).
Who is sponsoring clinical trial NCT00767689?
This trial is sponsored by Cook County Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00767689's enrollment target sits among peer trials
6 1983rd of 2000 higher than 13 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI